<DOC>
	<DOC>NCT00652379</DOC>
	<brief_summary>The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.</brief_summary>
	<brief_title>Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age &gt; 18 Diagnosed with acromegaly Safe anticonceptive for fertile women Well controlled on somatostatin analog (a serum IGFI within normal range a nadir GH &lt; 0.5 Âµg/l.) Pregnancy Liver disease Diabetes mellitus type I Magnetic or electronic implants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Glucose tolerance</keyword>
	<keyword>Body composition</keyword>
	<keyword>Growth Hormone</keyword>
</DOC>